WS
VYNT

Wedbush Securities’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Wedbush Securities’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-160
Closed -$6K – 1042
2019
Q1 		$6K Sell
160
-97
-38% -$3.99K ﹤0.01% 921
2018
Q4 		$9K Sell
257
-73
-22% -$6.15K ﹤0.01% 827
2018
Q3 		$52K Sell
330
-19
-5% -$2.81K 0.01% 870
2018
Q2 		$47K Buy
349
+30
+9% +$4.54K 0.01% 841
2018
Q1 		$79K Hold
319
– – 0.01% 769
2017
Q4 		$88K Hold
319
– – 0.01% 795
2017
Q3 		$129K Sell
319
-83
-21% -$43.3K 0.02% 764
2017
Q2 		$238K Sell
402
-178
-31% -$104K 0.03% 641
2017
Q1 		$357K Sell
580
-23
-4% -$8.18K 0.05% 469
2016
Q4 		$122K Buy
+603
New +$137K 0.02% 729

Other funds holding VYNT

PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Wedbush Securities's VYNT Position: Q2 2019 in Review

Wedbush Securities sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2019, closing a stake of 160 shares — an estimated $6K sold.

Wedbush Securities first reported a position in VYNT in Q4 2016 and held it in 10 quarters. The position peaked at $357K in Q1 2017. 23 funds tracked by Wall St. Rank hold VYNT as of Q2 2019.

  • Wedbush Securities reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Wedbush Securities sold 160 Vyant Bio, Inc. Common Stock shares in Q2 2019, an estimated $6K.
  • Wedbush Securities first reported a position in Vyant Bio, Inc. Common Stock in Q4 2016 and held it in 10 quarters.
  • Wedbush Securities's Vyant Bio, Inc. Common Stock position peaked at $357K in Q1 2017.
  • 23 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2019.

Based on Wedbush Securities's 13F filing for Q2 2019, filed 1 Aug 2019.